The EQ-5D is a multiattribute health status measure that can be used to derive preferencesbased index scores for HRQL assessment. The objective of the study was to elicit the Visual Analogue Scale (VAS) and the Time Trade-off (TTO) scores of minor (independent after stroke) and major (dependent after stroke) stroke survivors, from social tariffs obtained from general population samples. METHODS: A cross-sectional study of 350 stroke survivors was conducted in Spain. They were stratified as minor and major stoke, depending if they required help from another person for everyday activities. The EQ-5D questionnaire was administered to stroke survivors. Responses to the questionnaire were converted in single scores along a continuum extending from death (0.0) to full health (1.0). RESULTS: The VAS and the TTO scores varied considerably across minor and major stroke survivors. The minor and major stroke survivor, mean VAS scores were 0.71 (0.23) and 0.33 (0.27) respectively and mean for TTO scores were 0.73 (0.28) and 0.21 (0.43) respectively. Minor and major stroke survivors were a significant predictor of VAS and TTO scores. CONCLUSIONS: Minor and major stroke survivors had a substantial influence on VAS and TTO scores, as measured by the EQ-5D. Patients with major stroke had much lower scores. Our data support the EuroQol as a useful measure of health status after stroke. Its simplicity is a definite advantage, because many stroke survivors find more complex instruments difficult to complete without help.
OBJECTIVE:
To project the impact of Ezetimibe 10 mg (EZ10) co-administration for typical CHD patient not attaining TC goal with simvastatin 10 mg (S10) monotherapy in Finland on remaining life expectancy, mean TC reduction, and percent reaching goal.
METHOD:
A decision-analytic model is used to project benefits of lipid therapy. Clinical trial data on the distri-bution of TC changes was used to project the percent of patients reaching TC goal with ezetimibe co-administered with current statin therapy compared to titration (up to the maximum approved dose of Simvastatin 80 mg) to attain goal TC. Impact of TC changes on life expectancy was projected using Framingham risk equations and noncoronary mortality rates from Statistics Finland. In the base case the model was run for a 55 year old male on treatment with S10 and having TC = 6 mmol/L, and HDL = 1.1 mmol/L. The benefits were also obtained for men and women aged 35 to 75 years with TC 5.5 to 8.0 mmol/L. RESULTS: For a 55-year-old male CHD patient with TC = 6 mmol/L while on S10, Ezetimibe coadministration with simvastatin is projected to increase the remaining life expectancy from 10.8 to 11.24 years compared to statin titration where 42% not at goal are titrated at each dose (titration strategy I) and from 11.09 to 11.24 years compared to statin titration where all patients not at goal were titrated to attain goal (titration strategy II). Projected additional patients at TC goal per 100 treated and mean TC reduction are 10 and 3.66% for titration strategy I, 57 and 14.5% for titration strategy II, and 65 and 18.28% for EZ10 co-administration with S10. CONCLUSION: For the patient profile studied EZ10 co-administration with current statin is projected to bring more patients to goal and may increase survival time compared to titrating statin.
